Brought to you by 
Chiasma nets $94.7mm in oversubscribed IPO
16 Jul 2015
Executive Summary
Chiasma Inc. (oral orphan drugs for diseases requiring frequent dosing) netted $94.7mm in its initial public offering of 6.4mm shares at $16, above its anticipated sale of 5.4mm shares at a $13-15 range. Some existing investors bought 1.7mm of the IPO shares.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Chiasma nets $94.7mm in oversubscribed IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice